Cited by 773PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 129 of the 131 references it cites were found in a registry or an index.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Polivka, Jiri, Janku, Filip·2014·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2013.12.004

Open this paper in CoChat — free account

Abstract

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2013.12.004

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879

Show all 131 references

Research works printed but not linked: 1

Janku, 2011, Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors, Cancer Res, 71

Sorted by citations

Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940
RETRACTED ARTICLE: Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway
Zhang, X., Wang, S., Wang, H., Cao, J., Huang, X., Chen, Z., Xu, P., Sun, G., Xu, J., Lv, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0935-5 · Cited by 832
Retracted
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 818
Health benefits of polyphenols: A concise review
Rana, A., Samtiya, M., Dhewa, T., Mishra, V., & Aluko, R. E. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14264 · Cited by 840
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 659
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 631
Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies
Patil, P. C., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S. S., Dubey, R., Singh, H. N., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 441
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 367
mTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 381
The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances
Saraei, P., Asadi, I., Kakar, M. A., & Moradikor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 361
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 351
RETRACTED: Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway
Zhou, J., Jiang, Y., Chen, H., Wu, Y., & Zhang, L. (2019) · Cell Proliferation · doi:10.1111/cpr.12739 · Cited by 322
Retracted
Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
Rozengurt, E., Soares, H. P., & Sinnet-Smith, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0330 · Cited by 317
Formononetin: A Review of Its Anticancer Potentials and Mechanisms
Tay, K. C., Tan, L. T., Chan, C. K., Hong, S. L., Chan, K., Yap, W. H., Pusparajah, P., Lee, L., & Goh, B. H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00820 · Cited by 306
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-È., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 303
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 313
Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence
Xu, Y., Li, N., Xiang, R., & Sun, P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.004 · Cited by 282
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 338
Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer
Liao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 299
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Jankú, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 247
RETRACTED ARTICLE: Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression
Weng, M.-L., Chen, W.-K., Chen, X.-Y., Lu, H., Sun, Z.-R., Yu, Q., Sun, P.-F., Xu, Y.-J., Zhu, M.-M., Jiang, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15795-8 · Cited by 242
Retracted
Glutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 242
Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways
Yong, X., Tang, B., Li, B., Xie, R., Hu, C.-J., Luo, G., Qin, Y., Dong, H. F., & Yang, S. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0111-0 · Cited by 236
Molecular targets of curcumin for cancer therapy: an updated review
Kasi, P. D., Rajavel, T., Skalicka‐Woźniak, K., Nabavi, S. F., Daglia, M., Bishayee, A., Pazoki–Toroudi, H., & Nabavi, S. M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5183-y · Cited by 223
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben‐Yehuda, O., & Moslehi, J. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 208
Radiation-induced signaling pathways that promote cancer cell survival (Review)
HEIN, A. L., OUELLETTE, M. M., & YAN, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2614 · Cited by 201
HPV: Molecular pathways and targets
Gupta, S., Kumar, P. N., & Das, B. C. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.03.003 · Cited by 202
Mechanistic Understanding of Curcumin’s Therapeutic Effects in Lung Cancer
Tajuddin, W. N. B. W. M., Lajis, N. H., Abas, F., Othman, I., & Naidu, R. (2019) · Nutrients · doi:10.3390/nu11122989 · Cited by 162
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
Zhang, S., Song, X., Cao, D., Xu, Z., Fan, B., Che, L., Hu, J., Chen, B., Dong, M., Pilo, M. G., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.006 · Cited by 152
Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects
Stanciu, S., Radu, F. I., Ștefani, C., Miricescu, D., Stănescu-Spînu, I.-I., Greabu, M., Totan, A., & Jinga, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710132 · Cited by 149
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme
Polívka, J., Polívka, J., Holubec, L., Kubíková, T., Přibáň, V., Hes, O., Pivovarčíková, K., & Třešková, I. (2017) · Anticancer Research · doi:10.21873/anticanres.11285 · Cited by 145
CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9
Gao, Y., Guan, Z., Chen, J., Xie, H., YANG, Z., Fan, J., Wang, X., & Li, L. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3041 · Cited by 136
The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
Riquelme, I., Tapia, Ó., Espinoza, J. A., Leal, P., Buchegger, K., Sandoval, A., Bizama, C., Araya, J. C., Peek, R. M., & Roa, J. C. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0066-5 · Cited by 135
PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma
Wu, Y., Zhang, Y., Qin, X., Geng, H., Zuo, D., & Zhao, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105195 · Cited by 132
A prodrug of green tea polyphenol (–)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer
Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127
Bioactive Polyphenols and Neuromodulation: Molecular Mechanisms in Neurodegeneration
Meo, F. D., Valentino, A., Petillo, O., Peluso, G., Filosa, S., & Crispi, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072564 · Cited by 131
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 129
Underlying Mechanisms for Distant Metastasis - Molecular Biology
Pachmayr, E., Treese, C., & Stein, U. (2017) · Visceral Medicine · doi:10.1159/000454696 · Cited by 128
The PI3K/AKT pathway promotes fracture healing through its crosstalk with Wnt/β-catenin
Dong, J., Xu, X., Zhang, Q., Yuan, Z., & Tan, B. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112137 · Cited by 127
Glutamine Metabolism in Cancer
Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 134
Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer
Quan, Z., Yang, Y., Zheng, H., Zhan, Y., Luo, J., Ning, Y., & Fan, S. (2022) · Journal of Cancer · doi:10.7150/jca.77619 · Cited by 129
Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins
Haręża, D. A., Wilczyński, J. R., & Paradowska, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031818 · Cited by 138
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119
Transcript and protein expression decoupling reveals RNA binding proteins and miRNAs as potential modulators of human aging
Wei, Y.-N., Hu, H.-Y., Xie, G.-C., Fu, N., Ning, Z.-B., Zeng, R., & Khaitovich, P. (2015) · Genome Biology · doi:10.1186/s13059-015-0608-2 · Cited by 117
A multi-targeted approach to suppress tumor-promoting inflammation
Samadi, A. K., Bilsland, A. E., Georgakilas, A. G., Amedei, A., Amin, A., Bishayee, A., Azmi, A. S., Lokeshwar, B. L., Grue, B., Panis, C., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.006 · Cited by 118
Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future Perspectives
Uifălean, A., Schneider, S., Ionescu, C. M. L., Lalk, M., & Iuga, C. A. (2015) · Molecules · doi:10.3390/molecules21010013 · Cited by 111
Asiatic acid attenuates CCl 4 -induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways
Wei, L., Chen, Q., Guo, A., Fan, J., Wang, R., & Zhang, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.04.016 · Cited by 109
Signaling pathways in HPV‐associated cancers and therapeutic implications
Chen, J. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1823 · Cited by 108
Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells
Silva, V. R., Santos, L. D. S., Dias, R. B., Quadros, C. A., & Bezerra, D. P. (2021) · 癌症：英文版 · doi:10.1002/cac2.12235 · Cited by 106
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1320-y · Cited by 106
Role of Forkhead Box Class O proteins in cancer progression and metastasis
Kim, C. G., Lee, H., Gupta, N., Ramachandran, S., Kaushik, I., Srivastava, S., Kim, S.-H., & Srivastava, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.007 · Cited by 100
Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma
Rahmani, F., Ziaeemehr, A., Shahidsales, S., Gharib, M., Khazaei, M., Ferns, G. A., Ryzhikov, M., Avan, A., & Hassanian, S. M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29333 · Cited by 103
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma
Chen, Z., Lin, T., Liao, X., Li, Z., Lin, R., Qi, X., Chen, G., Sun, L., & Lin, L. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00423-4 · Cited by 99
PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma
Mohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., & Påhlman, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0708 · Cited by 104
Celastrol and Its Role in Controlling Chronic Diseases
Venkatesha, S. H., & Moudgil, K. D. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41334-1_12 · Cited by 99
Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Ye, R., Dai, N., He, Q., Guo, P., Xiang, Y., Zhang, Q., Hong, Z., & Zhang, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.065 · Cited by 98
Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
Xu, S., Liu, D., Chang, T., Wen, X., Ma, S., Sun, G., Wang, L., Chen, S., Xu, Y., & Zhang, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.938259 · Cited by 97
At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications
Houck, A. L., Seddighi, S., & Driver, J. A. (2018) · Current Aging Science · doi:10.2174/1874609811666180223154436 · Cited by 96
Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway
Li, D., Wang, G., Jin, G., Yao, K., Zhao, Z., Bie, L., Guo, Y., Li, N., Deng, W., Chen, X., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3969 · Cited by 95
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
Barra, F., Evangelisti, G., Desideri, L. F., Domenico, S. D., Ferraioli, D., Vellone, V. G., Cian, F. D., & Ferrero, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1558202 · Cited by 96
m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer
Zhao, Q., Zhao, Y., Hu, W., Zhang, Y., Wu, X., Lu, J., Li, M., Li, W., Wu, W., Wang, J., et al. (2020) · Theranostics · doi:10.7150/thno.42971 · Cited by 95
PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
Bădoiu, S. C., Greabu, M., Miricescu, D., Stănescu-Spînu, I.-I., Ilinca, R., Bălan, D. G., Balcangiu‐Stroescu, A.-E., Mihai, D. A., Văcăroiu, I. A., Ștefani, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098391 · Cited by 101
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer
Weisner, J., Landel, I., Reintjes, C., Uhlenbrock, N., Trajkovic‐Arsic, M., Dienstbier, N., Hardick, J., Ladigan, S., Lindemann, M., Smith, S. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2861 · Cited by 99
Autophagy in acute leukemias: A double-edged sword with important therapeutic implications
Evangelisti, C., Evangelisti, C., Chiarini, F., Lonetti, A., Buontempo, F., Neri, L. M., McCubrey, J. A., & Martelli, A. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.023 · Cited by 96
Beyond controlling cell size: functional analyses of S6K in tumorigenesis
Wu, X., Xie, W., Xie, W., Wei, W., & Guo, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05081-4 · Cited by 96
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies
Mossenta, M., Busato, D., Bo, M. D., & Toffoli, G. (2020) · Cancers · doi:10.3390/cancers12061668 · Cited by 93
MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
Oliynyk, G., Ruiz-Pérez, M. V., Sainero‐Alcolado, L., Dzieran, J., Zirath, H., Gallart‐Ayala, H., Wheelock, C. E., Johansson, H. J., Nilsson, R., Lehtiö, J., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.020 · Cited by 92
Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence
Peired, A. J., Campi, R., Angelotti, M. L., Antonelli, G., Conte, C., Lazzeri, E., Becherucci, F., Calistri, L., Serni, S., & Romagnani, P. (2021) · Cancers · doi:10.3390/cancers13184588 · Cited by 92
Rho, ROCK and actomyosin contractility in metastasis as drug targets
Rodríguez‐Hernández, I., Cantelli, G., Fanshawe, B., & Sanz‐Moreno, V. (2016) · F1000Research · doi:10.12688/f1000research.7909.1 · Cited by 90
Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems
Tavakol, S., Ashrafizadeh, M., Deng, S., Azarian, M., Abdoli, A., Motavaf, M., Poormoghadam, D., Khanbabaei, H., Afshar, E. G., Mandegary, A., et al. (2019) · Biomolecules · doi:10.3390/biom9100530 · Cited by 92
HIV‐1, HAART and cancer: A complex relationship
Shmakova, A., Germini, D., & Vassetzky, Y. S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32730 · Cited by 86
Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma
Yu, H., Qiu, Y., Pang, X., Li, J., Wu, S., Yin, S., Han, L., Zhang, Y., Jin, C., Gao, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0498 · Cited by 86
Reactive Oxygen Species-Mediated c-Jun NH 2 -Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy via Regulation of the Beclin-1/Bcl-2 Interaction
Zhong, L., Shu, W., Dai, W., Gao, B., & Xiong, S. (2017) · Journal of Virology · doi:10.1128/jvi.00001-17 · Cited by 83
Identification of new immune target and signaling for cancer immunotherapy
Narote, S., Desai, S. A., Patel, V. P., Deshmukh, R., Raut, N., & Dapse, S. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.03.004 · Cited by 95
The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine
Vo, T. T. T., Vo, Q. C., Tuan, V. P., Wee, Y., Cheng, J. H.-C., & Lee, I. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102124 · Cited by 81
The Heterogeneity of Lipid Metabolism in Cancer
Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_3 · Cited by 80
Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway
Gan, L., Qiu, Z., Huang, J., Li, Y., Huang, H., Xiang, T., Wan, J., Hui, T., Lin, Y. S., Li, H., et al. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15943 · Cited by 79
LncRNA‐XIST/microRNA‐126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma
Cheng, Z., Luo, C., & Guo, Z. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29440 · Cited by 78
Drug discovery targeting the mTOR pathway
Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77
Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition
Ko, J., Nam, D., Um, J., Jung, S. Y., Sethi, G., & Ahn, K. S. (2018) · Molecules · doi:10.3390/molecules23071601 · Cited by 76
Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression
Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 76
miR-182 and miR-135b Mediate the Tumorigenesis and Invasiveness of Colorectal Cancer Cells via Targeting ST6GALNAC2 and PI3K/AKT Pathway
Li, J., Luo, S., Ren, X. S., Li, Y., Hu, J., Liu, B., Zhao, L., Shan, Y., & Zhou, H. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4755-z · Cited by 75
Therapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 82
Anticancer natural medicines: An overview of cell signaling and other targets of anticancer phytochemicals
Akhtar, M. F., Saleem, A., Rasul, A., Baig, M. M. F. A., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173488 · Cited by 73
PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 79
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 74
Interferons: Reprogramming the Metabolic Network against Viral Infection
Raniga, K., & Liang, C. (2018) · Viruses · doi:10.3390/v10010036 · Cited by 74
The epigallocatechin gallate derivative Y6 inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/ HIF-1α/VEGF dependent pathways
Liao, Z.-H., Zhu, H., Chen, Y., Chen, R.-L., Fu, L.-X., Li, L., Zhou, H., Zhou, J., & Liang, G. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112852 · Cited by 77
Casticin-Induced Inhibition of Cell Growth and Survival Are Mediated through the Dual Modulation of Akt/mTOR Signaling Cascade
Lee, J. H., Kim, C., Um, J., Sethi, G., & Ahn, K. S. (2019) · Cancers · doi:10.3390/cancers11020254 · Cited by 74
Chlorogenic acid inhibits proliferation and induces apoptosis in A498 human kidney cancer cells via inactivating PI3K/Akt/mTOR signalling pathway
Wang, X., Liu, J., Xie, Z., Rao, J., Xu, G., Huang, K., Li, W., & Yin, Z. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13095 · Cited by 70
Cell Signaling Pathways That Promote Radioresistance of Cancer Cells
Ouellette, M. M., Zhou, S., & Yan, Y. (2022) · Diagnostics · doi:10.3390/diagnostics12030656 · Cited by 74
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression
Ai, X., Xiang, L., Huang, Z., Zhou, S., Zhang, S., Zhang, T., & Jiang, T. (2018) · Biological Research · doi:10.1186/s40659-018-0202-7 · Cited by 65
Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme
Behl, T., Sharma, A., Sharma, L. K., Sehgal, A., Singh, S., Sharma, N., Zengin, G., BUNGAU, S. G., Toma, M. M., Gîtea, D., et al. (2021) · Cancers · doi:10.3390/cancers13112765 · Cited by 67
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 67
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver
Li, X., Tao, J., Cigliano, A., Sini, M., Caldéraro, J., Azoulay, D., Wang, C., Liu, Y., Jiang, L., Evert, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3546 · Cited by 65
BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer
Shu, X., Zhan, P., Sun, L., Yu, L., Liu, J., Sun, L., Yang, Z., Ran, Y., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.659260 · Cited by 64

Authors: Polivka, J., & Janku, F.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2014-05
Volume: 142
Issue: 2
Pages: 164-175
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2013.12.004
OpenAlex: W2132052921
Cited by: 765
References: 131
Citations by year: 2026: 20 · 2025: 31 · 2024: 41 · 2023: 71 · 2022: 56 · 2021: 90 · 2020: 80 · 2019: 103 · 2018: 63 · 2017: 71 · 2016: 51 · 2015: 59 · 2014: 28
FWCI: 4.39
Type: journal article
Language: en
Open access: closed
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: PI3K/AKT/mTOR pathway, targeted cancer therapy, molecular targets, PI3K inhibitors, mTOR inhibitors, everolimus, temsirolimus, MAPK signaling, oncogenic mutations, tumor suppressor, prognostic factors, predictive biomarkers, precision oncology, carcinogenesis
MeSH terms: Phosphoinositide-3 Kinase Inhibitors, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Design, Signal Transduction, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks